Skip to content

Comparison of Gait Training Methods in Sub-acute Stroke and Spinal Cord Injury

Comparison of Intensity and Step Count of Gait Training Modalities in the Inpatient Rehabilitation Setting in Sub-acute Central Nervous System Injury

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06169657
Enrollment
0
Registered
2023-12-13
Start date
2024-09-01
Completion date
2025-12-31
Last updated
2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incomplete Spinal Cord Injury, Stroke

Keywords

Stroke, Incomplete Spinal Cord Injury, Gait Rehabilitation, Exoskeleton, Balance

Brief summary

The purpose of the project is to compare intensity (minutes in target heart rate zone) and steps per session across three gait training modalities, including body-weight supported treadmill training (BWSTT), overground gait training with body weight-support (BWS), and overground gait training utilizing a lower extremity exoskeleton, between patients presenting with varying functional ambulation capacities in the inpatient setting. Additionally, the researchers will compare physical therapist (PT) burden across these modalities and patient functional presentation levels.

Detailed description

Aim 1 of this study is to measure stepping repetition and intensity via heart rate of three gait-training modalities utilized with patients in the subacute phase of stroke and iSCI during inpatient rehabilitation in order to guide therapists through clinical decision-making of selecting the optimal intervention for patients based on functional presentation. Aim 2 of this study is to measure therapist burden across each gait training modalities, as this is an additional factor that contributes to the number of steps taken and intensity experienced by the patient. The gait training modalities assessed will include BWSTT, overground gait training with a lower extremity exoskeleton, and overground gait training with BWS. The participants' functional level will be classified by gait speed obtained via the 10 meter walk test (10MWT), a standardized assessment commonly used in rehabilitation. These functional classification categories include household ambulator (low level) and limited community ambulator (high level), determined by Fritz et al. 2009. The researchers hypothesize that low functioning/household ambulators will achieve more minutes in high-intensity training zones utilizing the exoskeleton due to the enhanced participation and increased weight-bearing the device supports compared to the other modalities. In addition, a greater number steps will be achieved in this mode due to the exoskeleton's ability to decrease overall therapist burden compared to BWSTT and overground with BWS. In contrast, the researchers anticipate that steps per session and overall intensity will be decreased in high functioning/limited community ambulators due the unnecessary support the exoskeleton provides at this functional level. The researchers believe that high functioning/ limited community ambulators will achieve the highest number of steps and intensity during BWSTT due to the ability to increase challenges via treadmill parameters such as speed and incline while utilizing a harness for safety and bodyweight support only as necessary. In contrast, the researchers believe the amount of BWS and assistance a PT must provide relative to the patient's contribution to practice successful stepping during BWSTT will result in a lower intensity and number of steps achieved in low functioning/household ambulators.

Interventions

DEVICEBody-weight-supported treadmill training (BWSTT)

Walking on a treadmill in a harness with body weight support as needed

DEVICEEksoNR exoskeleton gait training

Walking in the EksoNR exoskeleton

DEVICEOverground gait training

Walking overground in a harness with body weight support as needed

Sponsors

Shirley Ryan AbilityLab
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-75 years old, inclusive * Medical clearance from primary medical team (signed Medical Clearance form) * Adequate cognitive function as determined by the NIH scale: score ≤1 on question 1b and score =0 on question 1c * Gait speed between 0-0.79 m/s * Informed consent provided by participant or POA * English speaking Additional Inclusion Criteria for patients post-stroke: * First stroke, ischemic or hemorrhagic, within the past six months * Unilateral, supratentorial stroke Additional Inclusion Criteria for patients iSCI: * ASIA C or D * Traumatic iSCI, within past six months

Exclusion criteria

* Severe aphasia limiting ability to express needs or discomfort verbally or nonverbally * History of or concurrent neurologic condition (i.e., stroke, SCI, PD, TBI, MS, etc.) * History of peripheral nerve injury * Severe knee, hip, or ankle osteoarthritis * Severe osteoporosis as indicated by physician medical clearance * Open wounds on skin surfaces in contact with exoskeleton or harness * Unstable spine or unhealed fractures * Weight bearing precautions * Unresolved deep vein thrombosis (DVT) * Pregnancy * Prisoners Additional

Design outcomes

Primary

MeasureTime frameDescription
Observation of Step countEach session through completion of study, up to 10 daysThe number of steps taken during each session will be measured using activity monitors/pedometers. These devices are small accelerometers that can be worn on a belt and/or on the ankle to record steps and Kcals during an activity. The therapist leading the intervention session will apply the ActiGraph at the beginning of each intervention session and remove it upon completion. A higher step count is a better outcome.
Observation of Time spent in age-predicted maximum high-intensity target heart rate zoneEach session through completion of study, up to 10 daysThe target range of 70-85% of age-predicted maximum heart rate will be calculated for each participant utilizing HR max = 208 - \[0.7 × age\] as developed by Tanka et al in 2001. The target range of 70-85% of age-predicted maximum heart rate will be calculated for each participant. The researchers will record the amount of time participants spend in their pre-calculated target zone during each gait training. The minimum amount of time would be 0 minutes and the maximum amount of time would be 60 minutes as this would be the total time of the session. More time spent in the maximum intensity zone target zone is a better outcome.
Observation of Time spent in age-predicted moderate-intensity target heart rate zoneEach session through completion of study, up to 10 daysThe target range of 50-70% of age-predicted maximum heart rate will be calculated for each participant utilizing HR max = 208 - \[0.7 × age\] as developed by Tanka et al in 2001. The target range of 50-70% of age-predicted maximum heart rate will be calculated for each participant. The researchers will record the amount of time participants spend in their pre-calculated target zone during each gait training. The minimum amount of time would be 0 minutes and the maximum amount of time would be 60 minutes as this would be the total time of the session. Less time spent in the moderate intensity pre-calculated target zone is a better outcome as the more minutes in the high intensity zone is the best outcome.
Observation of Time spent in age-predicted low-intensity target heart rate zoneEach session through completion of study, up to 10 daysThe target range of 50% of age-predicted maximum heart rate will be calculated for each participant utilizing HR max = 208 - \[0.7 × age\] as developed by Tanka et al in 2001. Low intensity equals 50% or less of age-predicted maximum heart rate and will be calculated for each participant. The researchers will record the amount of time participants spend in their pre-calculated target zone during each gait training. The minimum amount of time would be 0 minutes and the maximum amount of time would be 60 minutes as this would be the total time of the session. Less time spent in the low intensity zone is better as the goal is to achieve more minutes in high-intensity zone.

Secondary

MeasureTime frameDescription
Observation of Patient Intrinsic Motivation Inventory (IMI)Each session through completion of study, up to 10 daysThe Intrinsic Motivation Inventory (IMI) is a multidimensional measurement that measures participants' subjective experience related to a target activity in laboratory experiments. The instrument consists of seven subscale scores related to interest/enjoyment, perceived competence, effort/importance, felt pressure/tension, perceived choice, value/usefulness and relatedness while performing a given activity. 29 items, adapted from the standardized instrument, are addressed on a 7 point scale, 1-7, in which one indicates not at all and seven indicates very true. A higher score is better.
Observation of therapist maximum heart rateEach session through completion of study, up to 10 daysTherapist heart rate will be measured throughout each session as an indicator of burden. There is no standard minimum or maximum value, however a higher heart rate indicates increased therapist burden.
Observation of Minutes spent in equipment setup per sessionEach session through completion of study, up to 10 daysTotal time in minutes spent applying and removing equipment. The minimum amount of time would be 0 minutes and the maximum amount of time would be 60 minutes as this would be the total time of the session. Less time would be considered better as that indicates more time spent walking.
Observation of therapist Numerical Pain Rating Scale (NPRS)Each session through completion of study, up to 10 daysThe NPRS is used to measure the subjective report of pain intensity. It consists of an 11-point scale, 0-10, in which zero indicates no pain and ten indicates the most intense pain imaginable. A lower score is better, indicating less pain.
Observation of therapist maximum Borg Rating of perceived exertion (RPE)Each session through completion of study, up to 10 daysThe Borg Rating of Perceived Exertion is a tool to measure the subjective report of effort, exertion, and fatigue during physical work. It consists of a 15-point scale from 6-20, in which 6=no exertion and 20=absolute maximum exertion. It is presented to the participant in written format with descriptors to standardize the report of perceived exertion across tasks. A lower score is better, indicating less burden on the therapist.
Observation of Minutes spent in rest breaks per sessionEach session through completion of study, up to 10 daysTotal time in minutes the participant spends resting (not walking or applying/ removing equipment) between walking bouts. The minimum amount of time would be 0 minutes and the maximum amount of time would be 60 minutes as this would be the total time of the session. Less time would be considered better as that indicates more time spent walking.
Observation of Minutes spent steppingEach session through completion of study, up to 10 daysTotal time in minutes the participant spends walking (not including rest breaks or applying/ removing equipment) during a session. The minimum amount of time would be 0 minutes and the maximum amount of time would be 60 minutes as this would be the total time of the session. Less time would be considered better as that indicates more time spent walking.
Observation of Patient Borg Rating of perceived exertion (RPE)Each session through completion of study, up to 10 daysThe Borg Rating of Perceived Exertion is a tool to measure the subjective report of effort, exertion, and fatigue during physical work. It consists of a 15-point scale from 6-20, in which 6=no exertion and 20=absolute maximum exertion. It is presented to the participant in written format with descriptors to standardize the report of perceived exertion across tasks. An optimal score is between 14-20 as this indicates higher perceived walking intensity for the participant.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026